Tc 99m dianexin
Alternative Names: 99m-Tc-HYNIC annexin V; 99m-Tc-HYNIC dianexin; 99m-Tc-HYNIC-annexin A5; 99mTc-4,5-bis(thioacetamido)pentanoyl-annexin-V; 99mTc-BTAP-annexin-V; Apomate; Tc 99m annexin-V; Tc 99m-HYNIC annexin V; Technetium Tc 99m BTAP-annexin-V; Technetium Tc 99m HYNIC annexin VLatest Information Update: 31 Mar 2022
At a glance
- Originator Stanford University
- Class Calcium binding proteins; Organotechnetium compounds; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Technetium compounds
- Mechanism of Action Single-photon emission-computed tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Tissue degeneration
Most Recent Events
- 07 Nov 2006 AnorMED has been acquired by Genzyme Corporation
- 06 Jul 2004 North American Sicentific presented observations from an ongoing European clinical trial with Tc 99m dianexin in patients with non-small lung cancer
- 14 Oct 2003 North American Scientific announced preliminary data from an ongoing European study with Tc 99m dianexin